Hot Investor Mandate: Global Pharmaceutical Partner Seeks Novel Therapeutics and Platform Technologies Through Strategic Collaborations

21 Jul

The U.S.-based research and business development arm of a global pharmaceutical company serves as its international innovation and partnering platform. Rather than operating as a traditional venture capital investor, the firm identifies and evaluates external innovation to strengthen the parent company’s research and development pipeline. The firm collaborates with biotechnology and pharmaceutical companies worldwide through strategic partnerships, in-licensing, co-development, and other business development transactions to accelerate the advancement of innovative medicines. The firm focuses on therapeutic innovation across anti-infectives, central nervous system disorders, oncology, autoimmune diseases, and metabolic diseases.  

The firm is open to a broad range of therapeutic modalities and actively seeks novel drug candidates, platform technologies, and translational research programs that align with its strategic development priorities. The firm evaluates opportunities across preclinical and clinical development and pursues flexible partnership structures tailored to the needs of each program.  

From a company and management team perspective, the firm seeks partners with differentiated science, strong intellectual property, and compelling preclinical or clinical data supporting global development potential. The firm values companies with well-defined development strategies and innovative assets that can address significant unmet medical needs. Through its global development, regulatory, manufacturing, and commercialization capabilities, the firm works closely with partners to advance promising therapies toward international markets.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , , , ,

Hot Investor Mandate: VC Firm Invests Exclusively in Differentiated Therapeutics Across All Development Stages, Focusing on USA-Based Companies

21 Jul

The firm is a healthcare-focused venture capital firm based in the United States that invests in novel, differentiated therapeutics addressing significant unmet medical needs. The firm makes direct equity investments across the full development spectrum, from preclinical programs through clinical- and commercial-stage companies. The firm participates in Seed and first institutional rounds, later-stage private financings, crossover rounds, and PIPE transactions, with the capacity to invest up to approximately $15M over the life of an investment. The firm can act as a lead, co-lead, or co-investor and invests in both private and public companies.  

The firm focuses primarily on therapeutics in oncology, immunology, neurology, and rare diseases, while remaining open to other indications on a selective basis. The firm is stage-agnostic and prioritizes differentiated science, strong biological rationale, and programs with meaningful clinical and commercial potential. The firm seeks opportunities capable of addressing substantial unmet needs and reaching important development, regulatory, or commercial value-inflection milestones.  

From a company and management team perspective, the firm prefers experienced leadership teams with strong scientific and drug development expertise. The firm partners closely with scientists, entrepreneurs, and institutional co-investors and provides strategic support through its pharmaceutical and healthcare industry network. The firm seeks to help portfolio companies advance toward clinical milestones, strategic partnerships, follow-on financings, and successful exits.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , , , ,

Hot Investor Mandate: Cross-Border VC Firm Backs Life Science Companies in High Unmet Need Areas Including CNS, Immuno-Oncology, and More

21 Jul

The firm is a venture capital firm focused on supporting innovative healthcare companies across Asia, Australia, and North America. The firm invests in emerging life sciences businesses developing differentiated technologies and seeks opportunities with strong clinical and commercial potential. The firm takes a cross-border investment approach, helping portfolio companies access international capital, strategic partnerships, and global growth opportunities.  

The firm invests across biopharmaceuticals, medical devices, and digital health, with a particular interest in novel therapeutics addressing significant unmet medical needs. Areas of interest include immuno-oncology, neuroscience, and other high-impact therapeutic innovations. The firm is open to companies at all stages of clinical development and evaluates opportunities based on the strength of the underlying science, clinical potential, and market opportunity.  

From a company and management team perspective, the firm seeks innovative companies developing differentiated technologies with the potential to address meaningful unmet healthcare needs. The firm partners with management teams to support clinical development, commercialization, and international expansion, leveraging its cross-border network and experience in global healthcare investing. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , , , ,

Hot Investor Mandate: Early-Stage VC Firm Invests Up to $20M in Novel, First-In-Class Therapeutics Companies With US and Europe Focus 

21 Jul

The firm is a venture capital firm founded by experienced biotechnology entrepreneurs and focused exclusively on novel therapeutics. The firm invests at the earliest stages of company development, from Seed through late preclinical programs, and typically supports portfolio companies through clinical proof-of-concept before pursuing strategic exit opportunities. The firm generally makes initial equity investments of approximately $3M–5M, with the capacity to invest up to $15M–20M per company over the life of an investment. Investments are primarily made through equity, although convertible structures may be used selectively. While the firm’s current portfolio has a strong European focus, it takes a globally opportunistic approach and is expanding its focus toward North American opportunities.  

The firm invests exclusively in therapeutics and is both modality- and indication-agnostic. The firm prioritizes highly innovative drug candidates with differentiated mechanisms of action, compelling scientific rationale, and significant unmet medical need. Rather than focusing on specific therapeutic areas, the firm emphasizes development stage, scientific quality, and commercial potential. In addition to participating in financing syndicates, the firm is also active in company creation and the formation of new biotechnology ventures.  

From a company and management team perspective, the firm values experienced founders and leadership teams but does not impose strict requirements. The investment team works closely with portfolio companies on R&D strategy, capital allocation, financing, and corporate development, leveraging longstanding relationships with academic researchers, entrepreneurs, and biotechnology investors to help companies reach critical value-inflection milestones. The firm is open to acting as either a lead investor or co-investor depending on the opportunity.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , , , ,

Cross-Border Investor Luncheon at RESI Boston 2026

21 Jul

A private, screened luncheon for regional and international investors seeking syndicate partners.

RESI Boston | Wednesday, September 23 | 75 Seats

RSVP for Cross-Border Investor Luncheon Today

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022

Nearly nine out of ten life science startups fail. Not because the science is poor, but because they never connect to the right capital and strategic partners. Solving that is the reason Life Science Nation exists, and for more than fifteen years our work has come down to one thing: finding parties who need each other and matching them.

As some readers know, LSN has been addressing this pervasive dilemma through the LSN Labs Anchor Node Program. An Anchor Node combines LSN’s commercialization methodology and global capital formation network with a regional partner’s laboratories, entrepreneurial programs, and operating platform to produce investment-ready life science companies.

As we expanded the Anchor Node Program across Boston, Australia, Japan, Korea, the UK, and Brazil, a clear pattern emerged: regional partners constantly brought their local VCs to the table seeking international capital. At the same time, our own data across five global RESI events revealed that twenty percent of all partnering meetings were already investor-to-investor.

So we decided to formalize it, and provide a dedicated room for these partners to connect.

The Cross-Border Investor Luncheon, CBIL, is a private luncheon at RESI Boston for regional and international investors seeking syndicate partners. Regional investors have access to exceptional companies that often never reach international investors. International investors have access and reach that regional funds cannot build alone. Both are looking for the same thing across Asia, Europe, North America, and South America.

Attendance is screened. CBIL is for active investors seeking syndicate partners outside their own region, whether that means bringing international capital into local deals or gaining access to deal flow in regions where they have no presence.

Taking place on Wednesday, September 23, CBIL follows the format of the Global Family Office BioForum luncheon (GFOB luncheon takes place on Tuesday, September 22), now in its eighth year. Across those eight years, GFOB has brought family offices together to find each other, form alliances, and build syndicates. CBIL is the natural next step, applying the same private, curated format to the international investor community.

“The future of life science investing is not just finding great companies. It is finding great syndicate partners in the global arena.”


Dennis Ford, Founder and CEO, Life Science Nation

Wednesday, September 23   |   Private luncheon   |   Screened RSVP   |   75 seats

Every RSVP is reviewed. Request your seat today!

RSVP for Cross-Border Investor Luncheon Today

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , ,

Prepare for RESI Boston: Join Our Pre Conference Webinar Series

21 Jul

By Karen Deyo, VP of Product, Israel BD, LSN

karen-wp

Success at RESI Boston begins long before the conference starts. In the weeks leading up to the event, Life Science Nation is hosting a series of complimentary educational webinars designed to help innovators strengthen every aspect of their fundraising journey. From refining your messaging and marketing collateral to learning about emerging technologies, preparing your investor pitch, and navigating the RESI partnering system, these sessions will help you arrive at RESI Boston ready to maximize every opportunity.

Whether you are preparing for investor meetings, applying to the Innovator’s Pitch Challenge, or looking to sharpen your fundraising strategy, these webinars provide practical insights you can immediately put into action.

Branding and Messaging from Seed to Series B: Building Marketing Collateral That Attracts Investors

Monday, August 3 | 11:00 AM ET

Your marketing collateral is often the first impression investors have of your company. This interactive workshop explores how to build a compelling and consistent investment story across your tagline, elevator pitch, executive summary, one page tear sheet, and pitch deck.

Attendees will learn how to effectively communicate the three pillars’ investors evaluate: your technology, your market opportunity, and your business strategy while tailoring messaging for different audiences and strengthening materials through investor feedback.

Register: https://go.lifesciencenation.com/osolca

RESI Boston Partnering Tutorial

Tuesday, August 18 | 11:00 AM ET

The RESI partnering system is one of the most valuable tools available to attendees, but maximizing its potential requires the right strategy. Join the Life Science Nation team for a walkthrough of the partnering platform, including how to identify the best fit investors and strategic partners, manage outreach effectively, develop a successful meeting request strategy, follow up with purpose, and leverage RESI content to maximize your conference experience.

Registration: https://go.lifesciencenation.com/q5QmbZ

Educational Webinars Hosted by RESI Boston Sponsors

In addition to Life Science Nation’s educational workshops, RESI Boston sponsors are offering complimentary webinars that showcase their expertise and provide valuable insights for the life science community.

Biocytogen Webinar
RenSuper Workstation: An AI Driven Antibody Discovery Platform From Target to Antibody Leads in Click
Wednesday, August 26 | 1:00 PM ET

Discover how Biocytogen’s AI driven RenSuper Workstation integrates immunization, next generation sequencing, AI powered high throughput screening, and experimental validation to accelerate antibody discovery and deliver development ready antibody candidates.

Register: https://go.lifesciencenation.com/tooA7s

RSM Webinar – Life Sciences Strategic Managed Services Leader

RSM, a global consulting, tax, and assurance firm with deep expertise serving the life sciences industry, will host a complimentary webinar focused on helping emerging companies navigate growth, fundraising, and commercialization.

Tuesday, September 1 | 12:00 PM ET

Join RESI Boston sponsor RSM for a complimentary webinar featuring insights and expertise for life science companies preparing to grow, raise capital, and navigate today’s evolving business landscape.

Register: https://go.lifesciencenation.com/deHMNq

Maximizing the Power of Your Pitch

Thursday, September 17 | 11:00 AM ET

Just days before RESI Boston begins, this workshop will help innovators prepare one of the most important moments of fundraising: the investor pitch.

Learn practical techniques for crafting a compelling presentation, navigating the application process, delivering an engaging pitch, and confidently handling investor led questions and answers. Whether you are participating in the Innovator’s Pitch Challenge or meeting investors one on one, this session will help you present your company with confidence.

Register: https://go.lifesciencenation.com/akrBbw

Together, these webinars provide a comprehensive roadmap for RESI Boston preparation. From developing a compelling investment story and learning from industry experts to mastering the partnering platform and delivering a winning pitch, each session is designed to help you maximize every investor interaction before the conference begins.

Register for the webinars that best fit your fundraising needs and arrive at RESI Boston fully prepared to connect with investors, strategic partners, and industry leaders.

Tags: , , , , , , , , , , , ,

Finding the Right Investors Starts with the Right Data 

21 Jul

By Max Braht, VP of Business Development, LSN

Max-Braht-Headshot

For early-stage life science companies, fundraising success depends on connecting with investors who are actively looking for technologies like yours. That is why Life Science Nation (LSN) has spent years building one of the industry’s most comprehensive investor databases, designed specifically to help innovators identify the right capital partners.

Unlike generic databases built through web scraping, the LSN Investor Database is curated directly through 1:1 interviews with investors and strategic in-licensors, providing startups with insights that go far beyond basic contact information or what you find on an investor’s website. Each investor profile includes valuable details such as typical check size, preferred modalities and indications, stage of development, geographic focus, and more, allowing companies to build a highly targeted fundraising strategy.

The database includes more than 4,000 global investment firms across 10 distinct investor categories and over 12,000 investor contacts spanning therapeutics, medical devices, diagnostics, digital health, and other life science sectors. Whether you are raising a Seed, Series A, or Series B round, identifying investors who are an actual fit can save significant time and improve the quality of your outreach.

Not sure where to begin? Life Science Nation is offering a complimentary investor search to help companies uncover potential investors that may not already be on their radar. The search demonstrates how the LSN Investor Database can provide each company with a curated list of investors matched to their technology and stage of development, along with contact information to then go out and execute on a fundraising campaign.

LSN is also happy to offer a free Fundraising Readiness Assessment through our internally developed AI Agent. The assessment will generate a 6-page report that can be used to help transition your companies’ story from an “interesting technology” into a compelling and ultimately investable company.

Book your free investor search today or complete the AI assessment to take the first step toward building a more focused and effective fundraising campaign.

Book Your Free Investor Search Today

Tags: , , , , , , , , , , , , , , ,

← Older Entries